Phase I Study Results for Qilu Pharmaceutical’s Iparomlimab (QL1604) Now Published

Recently, the results of the Phase I study for iparomlimab, developed by Qilu Pharmaceutical Co., Ltd. were published online in the academic journal Frontiers in Immunology.